6-month response status* | 12-month response status* | ||||
---|---|---|---|---|---|
Characteristics | All participants (n = 22)*† | Responder (n = 9) | Nonresponder (n = 12) | Responder (n = 10) | Nonresponder (n = 11) |
Age, yr | 46.41 ± 14.35 | 37.44 ± 11.38‡ | 52.50 ± 13.65‡ | 40.80 ± 15.20 | 50.82 ± 12.88 |
Sex, M/F | 12/10 (54.50/45.50) | 4/5 (44.44/55.55) | 8/4 (66.67/33.33) | 5/5 (50/50) | 7/4 (63.63/36.36) |
TRD stage (IV/V) | 18 (81.82) | 8 (88.89) | 12 (100) | 9 (90) | 11 (100) |
Age at onset, yr | 22.5 ± 12.28 | 18.78 ± 10.66 | 24.33 ± 13.30 | 17.90 ± 8.79 | 25.64 ± 14.17 |
Time since onset, yr | 24 ± 16.54 | 18.67 ± 12.09 | 28.17 ± 18.68 | 22.90 ± 15.08 | 25.18 ± 18.44 |
Current episode, mo | 24 ± 17.63 | 19.56 ± 19.83 | 24.25 ± 16.36 | 17.40 ± 19.80 | 26.64 ± 14.97 |
Current medications, n | 3.40 ± 2.08 | 3.22 ± 2.39 | 3.42 ± 1.93 | 3.40 ± 2.41 | 3.27 ± 1.85 |
Past medications, n | 22.80 ± 11.94 | 17.56 ± 6.40 | 27.67 ± 13.47 | 18.90 ± 5.55 | 37.36 ± 14.82 |